IFNAR

The interferon-α/β receptor (IFNAR) is a receptor which binds type I interferons including interferon-α and -β. It is a heteromeric cell surface receptor composed of one chain with two subunits referred to as IFNAR1 and IFNAR2. Upon binding of type I IFNs, IFNAR activates the JAK-STAT signaling pathway. Interferon stimulation classically results in an anti-viral immune response. Type I IFNs share a common receptor consisting of two subunits, IFNAR1 and IFNAR2, which associate upon IFN binding. IFNAR2 is the major ligand binding component of the receptor complex, exhibiting nanomolar affinity to both IFNα and IFNβ subtypes. IFNAR1 and IFNAR2 belong to the class II helical cytokine receptor (hCR) family, which includes the receptor for type II IFN, tissue factor (TF), and IL10Rβ.

Targets for IFNAR

Products for IFNAR

Cat.No. Product Name Information
GC35440 AX-024 AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM.
GC19046 AX-024 hydrochloride AX-024 hydrochloride is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A.
GC14727 CCCP

Carbonyl cyanide m-chlorophenyl hydrazone, NSC 88124
Carbonylcyanide-3-chlorophenylhydrazone (CCCP) is a protonophore, which causes uncoupling of proton gradient in the inner mitochondrial membrane, thus inhibiting the rate of ATP synthesis.
GC63591 Cirsilineol Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4+ T cells.
GC38648 Cridanimod Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression.
GC65545 Cyclo(L-Phe-L-Pro)
GC72324 Dazukibart Dazukibart is a mouse-derived, humanized IgG1κ antibody targeting interferon beta 1 (IFNB1).
GC72791 Delmitide acetate

RDP-58 acetate
Delmitide (RDP58) acetate is an orally active d-isomer decapeptide with potent anti-inflammatory activity.
GC69056 Emapalumab

NI-0501

Emapalumab (NI-0501) is a humanized IgG1 monoclonal antibody that can non-competitively inhibit IFN-γ. Emapalumab has high affinity (Kd=1.4 pM) for both free IFN-γ and IFN-γ bound to its receptor. Emapalumab can be used in the study of hemophagocytic lymphohistiocytosis (HLH).
GC69093 Faralimomab

64G12

Faralimomab (64G12) is an immunomodulatory agent and a mouse anti-IFNA1 IgG1 monoclonal antibody.
GC72352 Fontolizumab Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody.
GC74077 HEI3090 HEI3090 is a P2X7R activator.
GC31799 IFN alpha-IFNAR-IN-1 (IFN-alpha and IFNAR interaction inhibitor) IFN alpha-IFNAR-IN-1 (IFN-alpha and IFNAR interaction inhibitor) is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR; inhibit MVA-induced IFN-α responses by BM-pDCs (IC50=2-8 uM).
GC60927 IFN alpha-IFNAR-IN-1 hydrochloride An inhibitor of the IFN-α-IFNAR protein-protein interaction
GC34307 IFN alpha-IFNAR-IN-1 hydrochloride (IFN-alpha and IFNAR interaction inhibitor)
GC36296 IFN-α Receptor Recognition Peptide 1

IRRP1
IFN-α Receptor Recognition Peptide 1 is a peptide of IFN-α associated with receptor interactions.
GC69259 IFN-γ Antagonist 1 acetate
IFN-β Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) acetate is an interferon β (IFN-β) antagonist. IFN-β Antagonist 1 inhibits the expression of HLR/DR antigens induced by IFN-β in Colo 205 cells, with an IC50 value of approximately 35 μM. IFN-β Antagonist 1 has potential applications in immunoregulation.
GC32019 Interferon receptor agonist Interferon receptor agonist (compound 6) is an interferon (IFN) receptor inducer.
GC65435 Monalizumab
Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A).
GC68293 ODN 1585
GC73317 ODN 1585 sodium ODN 1585 is a potent inducer of IFN and TNFα production.
GC69613 ODN 6016
ODN 6016 is a type of CpG-A oligonucleotide. ODN 6016 can induce the production of IFN-α and can be used to study immune disorders, including those caused by HIV-1. The sequence of ODN 6016 is T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G.
GC69615 ODN D-SL03
ODN D-SL03 is a type of Class C CpG oligonucleotide that can induce high levels of IFN-α production in PBMCs. ODN D-SL03 can activate human B cells, NK cells, and monocytes, upregulating the expression of CD80, CD86, and HLA-DR on subsets of human PBMCs. ODN D-SL03 also has the ability to inhibit tumor growth. The sequence for ODN D-SL03 is 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3'.
GC73326 ODN D-SL03 sodium ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α.
GC69889 Sifalimumab

MEDI-545; MDX 1103

Sifalimumab (MEDI-545) is a monoclonal antibody that targets and inhibits abnormal immune activity by binding to multiple subtypes of interferon-alpha. It can be used for research on systemic lupus erythematosus (SLE).